AllianceBernstein: Investors are getting ahead of themselves about healthcare
Antidiabetic drugs such as Ozempic have markets excited about healthcare, but AllianceBernstein’s Vinay Thapar calls for caution amongst the hype
Antidiabetic drugs such as Ozempic have markets excited about healthcare, but AllianceBernstein’s Vinay Thapar calls for caution amongst the hype
Social mobility is often missing from the diversity debate, writes LGIM’s James Crossley
To mark International Women’s Day, Interactive Investor’s Camilla Esmund explores whether the assumptions made about female investors are helpful or a hinderance
Convexity can ensure investors are capturing as much upside as possible
Markets are overlooking some glaring issues with AI that could result in dire consequences, writes Philip Gottschalk
As international relations become increasingly adversarial, a change in leader could bring about welcome and unwelcome consequences, writes Darius McDermott
Nations representing half of global GDP are holding elections this year – how will markets be affected?
Patience should help not just with the accumulation of wealth but with the preservation of capital too
Demand for GLP-1 medications is skyrocketing
Plenty of opportunities for eagle-eyed investors to uncover, writes Mark Preskett
The race for Consumer Duty has only just begun, writes Morningstar’s Steve Owen
Investors looking for long-term returns could find love at first sight with these five funds, says Square Mile’s John Monaghan